Published in Curr Diab Rep on August 01, 2017
Intensive insulin therapy in critically ill patients. N Engl J Med (2001) 40.00
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Intensive versus conventional glucose control in critically ill patients. N Engl J Med (2009) 26.30
Intensive insulin therapy in the medical ICU. N Engl J Med (2006) 22.37
Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med (2008) 19.93
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. START INVESTS P 13. N Engl J Med (2016) 7.04
Hypoglycemia and risk of death in critically ill patients. N Engl J Med (2012) 6.17
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med (2016) 5.87
American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care (2009) 5.41
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J (2005) 5.40
Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg (2003) 5.33
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation (2014) 5.32
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology (2011) 4.99
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA (2014) 4.50
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol (1995) 4.50
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med (2017) 4.18
Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care (2007) 4.15
A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med (2009) 4.13
Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2012) 4.02
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J (2011) 3.72
Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med (2008) 3.54
Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med (2013) 3.46
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med (2009) 3.29
Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care (2011) 3.06
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail (2006) 2.69
Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol (2007) 2.49
Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. Crit Care (2008) 2.34
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin (2008) 2.24
The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol (2011) 1.84
Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J (1996) 1.83
Hypoglycemia and cardiovascular risks. Diabetes Care (2011) 1.74
Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care (2013) 1.57
Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol (2014) 1.45
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging (2010) 1.40
The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care (2006) 1.39
Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes (2006) 1.35
Implications of the United kingdom prospective diabetes study. Diabetes Care (2003) 1.34
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol (2011) 1.21
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. JAMA Intern Med (2016) 1.21
Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction. Am Heart J (1981) 1.20
Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol (2013) 1.18
The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care (2009) 1.17
Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. Br Med J (Clin Res Ed) (1985) 1.15
Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol (2008) 1.13
Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res (2011) 1.12
Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care (2011) 1.10
Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv (2012) 1.10
Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail (2013) 1.01
Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract (2013) 1.00
Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care (2013) 1.00
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J (2015) 0.99
The use of exenatide in severely burned pediatric patients. Crit Care (2010) 0.96
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab (2013) 0.95
Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy (2012) 0.94
Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism (2015) 0.91
Dose-related effects of metformin on acid-base balance and renal function in patients with diabetes who develop acute renal failure: a cross-sectional study. Acta Diabetol (2016) 0.85
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation (2016) 0.84
Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol (2016) 0.81
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS). Diabetes Care (2017) 0.80
Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine (2015) 0.79
Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes Res Clin Pract (2011) 0.79
Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight. Nutr Metab Cardiovasc Dis (2016) 0.78
EVALUATION OF OUTCOMES AND COMPLICATIONS IN PATIENTS WHO EXPERIENCE HYPOGLYCEMIA AFTER CARDIAC SURGERY. Endocr Pract (2016) 0.78
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J Diabetes Complications (2014) 0.77
14. Diabetes Care in the Hospital. Diabetes Care (2017) 0.77
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care (2016) 0.76
Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab (2016) 0.76
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev (2016) 0.76
A Fatal Case of Metformin-associated Lactic Acidosis. Intern Med (2016) 0.76
Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. Circulation (2015) 0.75
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. Diabetes Ther (2016) 0.75
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Adv Ther (2016) 0.75